Trametenolic acid

Research use only, not for human use.

Trametenolic acid is a cytotoxic agent.It exhibits a mode of mixed inhibition with a K I of 0.9μM, K IS of 0.5μM, and an IC50 of 7.25μM.

Trametenolic acid is a cytotoxic agent.It exhibits a mode of mixed inhibition with a K I of 0.9μM, K IS of 0.5μM, and an IC50 of 7.25μM.Trametenolic acid and Betulin as a new candidate of potent tyrosinase inhibitors, can decrease tyrosinase activity and melanin content.

Trametenolic acid (1 mg/mL; 15-30 mins) induces the upregulation of autophagy-related proteins (Beclin-1, Atg12, and LC3) in B16-F1 cells by activating the ERK1/2 signaling pathway.Trametenolic acid (1 mg/mL; 24 hours; B16-F1 cells) has dual synergic mechanisms to exert an anti-melanogenetic effect.Trametenolic acid (0.1-4 mg/mL; 52 hours; B16-F1 cells) increase melanin synthesis by approximately 20% and 40% in cells transfected with siRNAs against mTOR and Atg5, respectively. Western Blot Analysis Cell Line:B16-F1 cells Concentration:1 mg/mL Incubation Time:15 and 30 mins Result:Increased the expression levels of phospho-p38, phospho-ERK1/2, Beclin-1, Atg12 and LC3 by approximately 46%, 10%, 48%, 126% and 49%, respectively.Western Blot Analysis Cell Line:B16-F1 cells Concentration:1 mg/mL Incubation Time:24 hours Result:Increased the expression of ERK1/2 and p-ERK1/2 and decreased MITF, tyrosinase, and TRP 1 levels.

——

——

Others

Other Targets

——

——

——

24160-36-9

456.7

C30H48O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (109.48 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years